Food and Drug Administration
Center for Drug Evaluation
and Research
Mary Glode, M.D. Steven
Ebert, Pharm. D.
Patricia
Chesney, M.D. Victor Santana, M.D. Norman Fost, M.D.
David
Danford, M.D. Robert Fink, M.D. Richard
Gorman, M.D., FAAP
Mark
Hudak, M.D. Susan Fuchs, M.D. Tal
Geva, M.D.
Judith O’Fallon, Ph.D. Craig
Sable, M.D. Vasken
Dilsizian, M.D.
Marilyn Siegel, M.D. Phillip
Moore, M.D. Mark Fogel,
M.D.
Ralph D’Agostino, Ph.D.
HHS Guest Guest Speaker Industry
Representative
Mario Stylianou, Ph.D. John Ring, M.D. Samuel Maldonado, M.D.
FDA Participants
Dianne Murphy, M.D. Julie Beitz, M.D. Shirley Murphy, M.D.
Susan
Cummins, M.D. Sally Loewke, M.D. ShaAvhree
Buckman, M.D.
Solomon
Iyasu, M.D. Hari Sachs, M.D.
These summary minutes for the February 3 & 4,
2004 meeting of the Pediatric Subcommittee of the Anti-Infective Drugs Advisory
Committee were approved on
I
certify that I attended the February 3 & 4, 2004 meeting of the Pediatric
Subcommittee of the Anti-Infective Drugs Advisory Committee, and that these minutes accurately reflect what
transpired.
___________//S//____________________ ___________//S//____________________
Thomas H. Perez, M.P.H., R.Ph. Patricia
Chesney, M.D.
Executive Secretary Chair
The Pediatric
Subcommittee of the AntiInfective Drugs Advisory Committee, of the Food and Drug Administration, Center for
Drug Evaluation and Research met February 3 & 4, 2004 at the Advisors and
Consultant’s Conference facility located at
On
The
Subcommittee and invited guests received a briefing document from the FDA in
preparation for this meeting.
There
were approximately 50 persons present at the meeting on February 3 & 4,
2004. The meeting was called to order at
Presentations began at
Adverse Event Reports per Section 17 of BPCA Solomon Iyasu, M.D., Lead Medical Officer
Division of Pediatric Drug Development
There were no Open
Public Hearing participants for the adverse events report session.
At
Pediatric Regulatory Update Susan Cummins, M.D., Lead Medical Officer
Division of Pediatric Drug Development
FDA Perspective Sally
Loewke, M.D., Acting Director
Div.
of Medical Imaging & Radiopharmaceutical Drug Products
University of
Cardiologist Perspective Tal Geva, M.D., Children’s
Hospital Boston
At
Contrast Enhanced Mark Fogel, M.D., The Children's
Cardiac Magnetic Resonance Imaging
Contrast
Enhanced Marilyn Siegel, M.D.
Cardiac Computed Tomography Washington University School of
Medicine
Contrast Enhanced Phillip Moore, M.D., UCSF
Children’s Hospital
Invasive Cardiac Imaging
After a 20 minute break the subcommittee reconvened at
Contrast Enhanced Cardiac Ultrasound Craig
Sable, M.D., Children’s National Medical Center
Radiopharmaceuticals in Vasken
Dilsizian, M.D., Univ. of Maryland School of Medicine
Nuclear Cardiac Imaging
At
Manuel Cerqueira, M.D., American Society of Nuclear Cardiology
Jack Rychik, M.D., American Society of Echocardiography
At
Drs. Julie Bietz, Susan
Cummins, and Sally Loewke thanked the committee for their efforts and
guidance. Joan Chesney, M.D., chair, adjourned the meeting at
The discussion will be made
available through the meeting transcripts and placed on the web in
approximately three weeks. Transcripts
may be accessed at: www.fda.gov/ohrms/dockets/ac/acmenu.htm.
Pediatric Advisory Subcommittee
of the Anti-Infective Drugs Advisory Committee
Questions for
1.
Given the
differences in cardiac disease processes that occur in adults and children, in
what cases (if any) can adult data from approved imaging drugs be extrapolated
to pediatric patients in whom cardiac imaging is needed? If so, in what cardiac disease states?
Members
of the panel expressed that in general it is not wise to extrapolate because of
differences existing relative to the maturity, functionality and disease in
pediatrics. However, each modality is
different and therefore how practical it is to extrapolate will vary. In the adolescent patient it may be
appropriate.
If further studies in
pediatric patients are needed, please further define the gaps in our knowledge
regarding imaging agents to be evaluated for cardiac imaging applications by discussing
the following questions.
2.
Please discuss
each of the following questions for cardiac computed tomography (CT).
What is the most relevant question for CT?
Safety,
dose, and flow. What is the minimum dose
that will provide the desired diagnostic image.
What is the flow rate that will provide the desired diagnostic image
a)
What imaging
agents need further study?
The
agents are proven. There is a need for
dose and flow rate studies
b)
What populations
should be studied?
Populations
should be studied by age, particularly the younger patients that have vascular,
valvular, complex heart disease, and or septal defects.
c)
What disease
states should be studied?
Same
as b)
d)
What endpoints
should be used?
Clinical
outcomes that will lead to further studies or termination of studies.
e)
How should a
trial be designed?
Trials
in animals should study dose and flow rates and look at enhancements and
diagnostics. Repeat the study in adults
to determine a starting dose.
f)
How should the
standard for comparison be defined? Is
there a gold-standard?
Cardiac
Catherization or Echocardiography.
3.
Please discuss
each of the following questions for cardiac magnetic resonance imaging (MRI).
What is the most relevant question for MRI?
For
anatomy the efficacy and safety relative to the dose, and perfusion and
viability in CHD.
a)
What imaging
agents need further study?
Gadolinium
b)
What populations
should be studied?
People
that are at most risk i.e. cardiac scarring.
Extracardiac in neonates, toddlers and children.
c)
What disease
states should be studied?
Extracardiac
abnormalities.
d)
What endpoints
should be used?
For
anatomy, surgery. For perfusion, nuclear
medicine.
e)
How should a
trial be designed?
Non-contrast,
followed by contrast with double dose of gadolinium as an adjunct, or studies
with ½, 1, or 1 ½ gadolinium dose to obtain information on dose response.
f)
How should the
standard for comparison be defined? Is
there a gold-standard?
Nuclear
scan and summation of all available information i.e. CT, autopsy.
4.
Please discuss each
of the following questions for cardiac ultra sound (
What is the most relevant question for ultra sound?
Improvement
in left ventrical opacification in patients difficult to image including those
with complex heart disease.
a)
What imaging agents
need further study?
Difinity
and Optisom
b)
What populations
should be studied?
Patients
with complex heart repairs and heart transplants. All ages down to 1 year.
c)
What disease
states should be studied?
Patiens
with repaired congenital heart defects and at risk for coronary heart disease
i.e. Kawasaki, heart transplant and CHD .
d)
What endpoints
should be used?
MRI
or nuclear medicine. Also use historical
controls starting with older patients.
e)
How should a
trial be designed?
Start
with patients having a poor prognosis.
Study with two arms, one arm at rest and the other arm with stress.
f)
How should the
standard for comparison be defined? Is
there a gold-standard?
Pre
and post evaluation and comparison of the patient.
5.
Please discuss
each of the following questions for cardiac nuclear imaging.
What is the most relevant question for nuclear imaging?
Physiologic
studies of perfusion in ischemia and perfusion viability.
a)
What imaging
agents need further study?
Thallium-201,
Technetium tracers, and PET tracers.
b)
What populations
should be studied?
Microcirculation
in pediatrics, neonates and premature infants.
c)
What disease
states should be studied?
Perfusion
ischemia and viability anomalies.
d)
What endpoints
should be used?
Endpoints
are physiologic and outcomes are symptom related. Anatomy as a gross basis, and how the patient
feel is a surrogate endpoint.
e)
How should a
trial be designed?
f)
How should the
standard for comparison be defined? Is
there a gold-standard?
Patients
improvement and recovery.
6.
Please discuss
each of the following questions for cardiac angiography.
What is the most relevant question for angiography?
Pediatric
studies should be part of the focus for new agents being developed.
a)
What imaging
agents need further study?
All
agents to determine smallest dose for each technique.
b)
What populations
should be studied?
Infants
and premature infants.
c)
What disease
states should be studied?
d)
What endpoints
should be used?
e)
How should a
trial be designed?
f)
How should the
standard for comparison be defined? Is
there a gold-standard?
Angiography
is the gold standard for adult ischemic heart disease.
7.
Please discuss
the relevance of new developments in the field of adult cardiac imaging that
may have potential application to the pediatric population? Can we anticipate the need for future drug
development for pediatric cardiac imaging?
Manganese,
and iron oxide agents for liver imaging.
Contrast
echo would be of value in the obese.
Non-contrast
MR would be of value for left ventricular mass and volume.
Contrast
MR would be of value for perfusion.